港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

諾誠健華

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

諾誠健華：公司新藥奧布替尼獲批在國內開展臨牀II期研究

港股異動 | 諾誠健華-B(09969)漲超7% 奧布替尼獲國家藥監局批准開展治療多發

金融界网站

諾誠健華－Ｂ(09969-HK)漲8.85%

諾誠健華奧布替尼獲國家藥監局批准開展治療多發性硬化臨牀II期研究

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/90009"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"90009","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90009\",,,,,undefined,":{"symbol":"90009","market":"HK","secType":"STK","nameCN":"諾誠健華","latestPrice":0,"timestamp":1748592000000,"preClose":0,"halted":9,"volume":0,"delay":0,"floatShares":25034000,"shares":225290000,"eps":0,"marketStatus":"休市中","change":0,"latestTime":"05-30 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1748827800000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1748568600000,1748577600000],[1748581200000,1748592000000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"諾誠健華","latestPrice":24.02,"timestamp":1748588400000,"preClose":22.99,"halted":0,"volume":7613700,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"90009\",,,,,undefined,":{"symbol":"90009","floatShares":25034000,"roa":"--","roe":"--","lyrEps":0,"shares":225290000,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/90009\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"90009\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2127072585","title":"諾誠健華：公司新藥奧布替尼獲批在國內開展臨牀II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127072585","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127072585?lang=zh_tw&edition=fundamental","pubTime":"2021-04-15 09:25","pubTimestamp":1618449900,"startTime":"0","endTime":"0","summary":"【诺诚健华：公司新药奥布替尼获批在国内开展临床II期研究】4月14日，诺诚健华宣布，公司旗下布鲁顿酪氨酸激酶（BTK）抑制剂奥布替尼用于治疗多发性硬化（MS）已经通过中国国家药品监督管理局（NMPA）...","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202104151885438464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","90009"],"gpt_icon":0},{"id":"2127252770","title":"港股異動 | 諾誠健華-B(09969)漲超7% 奧布替尼獲國家藥監局批准開展治療多發","url":"https://stock-news.laohu8.com/highlight/detail?id=2127252770","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127252770?lang=zh_tw&edition=fundamental","pubTime":"2021-04-14 15:41","pubTimestamp":1618386116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华-B宣布，公司旗下布鲁顿酪氨酸激酶抑制剂奥布替尼用于治疗多发性硬化已经通过中国国家药品监督管理局的临床研究用新药审评，获批在中国开展临床II期研究。截至发稿，诺诚健华涨7.03%，报20.55港元，成交额1.99亿港元。2020年11月，奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。","market":"hk","thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2021/04/14154132371805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["90009","09969"],"gpt_icon":0},{"id":"2127047291","title":"諾誠健華－Ｂ(09969-HK)漲8.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047291","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127047291?lang=zh_tw&edition=fundamental","pubTime":"2021-04-14 13:42","pubTimestamp":1618378920,"startTime":"0","endTime":"0","summary":"诺诚健华-B(09969-HK)截至13:41上涨8.85%，现报20.9港元，涨1.7港元。成交518万股，涉资1.054亿元。","market":"us","thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202104141884108958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","90009"],"gpt_icon":0},{"id":"2127047898","title":"諾誠健華奧布替尼獲國家藥監局批准開展治療多發性硬化臨牀II期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2127047898","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2127047898?lang=zh_tw&edition=fundamental","pubTime":"2021-04-14 09:37","pubTimestamp":1618364220,"startTime":"0","endTime":"0","summary":"2020年11月，奥布替尼获美国FDA批准开展治疗多发性硬化临床II期研究。奥布替尼是诺诚健华自主研发的具高度靶标选择性的新型BTK抑制剂，可用于治疗自身免疫性疾病，目前正在中国及美国进行多中心、多适应症的临床试验，显示了良好的靶点占有率和安全性。现有多个新药产品处于商业化、临床及临床前研发阶段。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/stock/relnews/hk/2021-04-14/doc-ikmyaawa9565055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_symbol","symbols":["90009","09969"],"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/90009\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"90009\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"90009\",market:\"HK\",delay:false,,,undefined,":{}}}